alexa
Reach Us +44-1235-425476
The Mucosal Immune Response To Plant-Derived Biopharmaceuticals | 3004
ISSN : 2153-2435

Pharmaceutica Analytica Acta
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

The Mucosal Immune Response to Plant-Derived Biopharmaceuticals

2nd International Conference on Pharmaceutics & Novel Drug Delivery Systems

Kathleen L. Hefferon

Accepted Abstracts: Pharm Anal Acta

DOI: 10.4172/2153-2435.S1.10

Abstract
Plants present a novel means by which large quantities of vaccine and therapeutic proteins can be produced in a safe and cost-effective manner. Biopharmaceuticals produced in plants are easy to store, require fewer timely and expensive purification steps, and lack the containment risks associated with proteins produced in animal or bacterial expression systems. Over the past decade, much progress has been made with respect to the development of vaccines, antibodies and other therapeutic proteins. This presentation outlines the steps involved in the engineering of a plant virus expression vector for transient expression of vaccine proteins and other therapeutics in plant tissue, and the advantages of this technology over the use of conventional transgenic plants. Expression of a vaccine protein using this expression vector system is described. An investigation into the basis of mucosal immunity using plant-based oral vaccines in preliminary clinical trials is also addressed. Expression levels and biological activity of a vaccine protein produced via a plant virus expression vector are described. The efficacy of this plant-based vaccine protein is compared to conventional vaccines. The presentation will conclude with a discussion of the future of plant-based vaccines and other therapeutic proteins in human and veterinary medicine with respect to commercial viability and as a tool to improve global public health.
Biography

Kathleen Hefferon received her PhD from the Department of Medical Biophysics, University of Toronto and continued her post-doctoral studies at Cornell University. Dr. Hefferon has worked on faculty at the Division of Nutritional Sciences at Cornell and has written two books on biopharmaceuticals in plants. She is currently teaching Virology at the University of Toronto, Faculty of Medicine.

Top